kimberly clark CEO Mike Hsu told CNBC’s Jim Cramer that the company plans to acquire the Tylenol maker. Kenview Even though the painkiller is under scrutiny by the Trump administration, it will create value for shareholders.
He also said that sales of Tylenol “we’re seeing some impact, but not as much as we would like” after Health and Human Services Secretary Robert F. Kennedy Jr. and President Donald Trump promoted unsubstantiated claims linking autism to the use of acetaminophen, the active ingredient in Tylenol, during pregnancy.
“I think this brand is very resilient,” Hsu said. “I’m still researching, and I’m not an expert on Tylenol, but I’ve heard that it’s a very effective and safe pain reliever, so I think consumers will respond accordingly.”
Kimberly-Clark, which makes consumer packaged products such as Kleenex and Huggies, and Kenvue, known for brands such as Neutrogena, Listerine and Band-Aid, along with Tylenol, announced the acquisition on Monday. The deal is valued at $48.7 billion and creates one of the world’s largest consumer staples companies.
Kimberly-Clark shares plunged 14.57% on the news, while Kenview rose more than 12%.
